Fair-balance and consumer-protection rules in patient-facing content

In 2015, Kim Kardashian posted to Instagram about Diclegis, the Duchesnay morning-sickness drug she had been paid to endorse. The caption named the product, said it worked for her, and carried no risk information at all. FDA's Office of Prescription Drug Promotion (OPDP) sent Duchesnay USA an untitled letter, and the correction cycle that followed reached far more people than the original post. One caption, no risk copy: that is the fair-balance problem in patient-facing creative, and social formats make it worse, not easier.

What fair balance asks of a format

Fair balance is a prominence standard. If a piece makes an efficacy claim about a prescription drug, the risk information has to travel in the same piece with comparable prominence: font size and contrast in print, on-screen duration and audio pacing in video, position in the scroll on mobile. Whether branded patient advertising is permitted at all in your market is settled elsewhere (the geography lesson forks that for you); this lesson assumes you are working in a market where it is, and asks whether the asset itself holds up.

Two FDA positions shape digital work specifically.

FDA's 2014 draft guidance on platforms with character space limitations says the benefit claim and the most serious risks must appear in the *same* message, however short, alongside a direct link to complete risk information. The uncomfortable corollary: if benefit and risk cannot both fit, the platform is not suitable for that claim. A one-click-away safety page does not rescue a caption that made a claim on its own.

The 2023 final rule on the major statement in DTC television and radio ads set a "clear, conspicuous and neutral" test: consumer-friendly language, audio that is understandable in volume and pacing, dual modality on TV (the major statement in both audio and text), and no distracting visuals or music competing with it during the risk read. The rule bans a specific old habit: burying the risk read under scenery, motion and a swelling soundtrack.

The practical test: if a viewer could leave your asset with an inflated sense of benefit or a diminished sense of risk, you have a fair-balance problem, regardless of what sits three taps away.

Anatomy of the Duchesnay violation

The OPDP letter is short and worth reading against your own social briefs. What it found:

• Efficacy claims with no risk information whatsoever in the post. Not subordinated risk copy, none.
• Omission of material facts, including that Diclegis had not been studied in women with hyperemesis gravidarum, the severe form of the condition many readers would assume was covered.
• Unsubstantiated presentation of effectiveness, framed as personal testimony rather than trial evidence.
• No indication limits, so the post read as an endorsement for pregnancy nausea generally.

None of these needed a new campaign to fix. They needed the caption to carry what a printed ad would have carried.

Two agencies in one caption

Paid influencer content sits under two regimes at once. OPDP wants fair balance and accurate indication. The Federal Trade Commission, under its endorsement guides (revised in 2023), wants the material connection disclosed clearly and conspicuously, close to the claim, not buried in a hashtag cluster or behind "more". A post can satisfy one and fail the other.

The failure modes cluster in a few places:

• The influencer edits the approved caption for tone and clips the risk sentence. The brand paid for the placement, so the brand carries the exposure.
• Story formats expire in 24 hours, which means your archived approval record no longer matches anything a reviewer can see, while screenshots circulate anyway.
• A follower comments that the drug helped a condition outside the label, and the brand account likes or replies warmly. Engagement on a controlled channel can pull that claim into your promotion.
• Audio-only formats (podcast reads) with no visual layer must carry the risks in speech, at a pace a listener can follow.

Rewriting for a scrolling feed

Before: "Morning sickness was brutal. My doctor prescribed [Drug] and it worked for me. #ad"

After: "#ad I'm working with [Company]. My doctor prescribed [Drug] for nausea and vomiting of pregnancy. It can cause drowsiness, so don't drive or operate machinery until you know how it affects you. [Drug] hasn't been studied in women with hyperemesis gravidarum. Full safety info: [link]"

The endorsement survives. What changed is that the claim is bounded by the indication, the most relevant risk sits in the same block of text a reader sees before tapping "more", and the disclosure leads rather than trails.

Design-level fixes for digital:

• Assume muted autoplay. Any risk statement carried only in audio effectively does not exist; superimpose it.
• Keep important safety information out of a separate scroll well that a mobile reader has to hunt for. Placement after a page turn is placement after a page turn, whether the page is paper or a tap.
• Set duration by legibility, not by legal minimum. Risk text that appears for less time than the benefit claim fails prominence parity even if every word is present.
• Do not seat risk copy next to co-pay offers, testimonials or unrelated promotions. Regulators read that adjacency as evasion.

🎬 [VIDEO: "FDA Regulation of Prescription Drug Advertising" - https://www.youtube.com/results?search_query=FDA+regulation+of+prescription+drug+advertising - search for FDA/OPDP explainer content covering how fair balance is assessed in real submitted materials]

Where consumer-protection and privacy law bites beyond drug advertising

Fair balance governs what you say. A second body of law governs what you collect while saying it, and it reaches assets that never mention a brand-name drug.

In February 2023 the FTC took action against GoodRx over sharing users' prescription and health information with Facebook, Google and other advertising platforms. GoodRx agreed to a $1.5 million civil penalty and a permanent bar on disclosing health data to third parties for advertising. The instructive part is the legal theory: GoodRx is not a HIPAA-covered entity, so the case ran on the FTC Act and the Health Breach Notification Rule instead. Pharma-funded symptom checkers, unbranded disease-awareness sites, patient support portals and co-pay eligibility flows sit in that same non-covered gap. The FTC amended the Health Breach Notification Rule in 2024 to make its application to health apps and connected products explicit, and to treat unauthorised disclosure, including disclosure for advertising, as a breach.

The concrete failure mode: a co-pay landing pagelanding pageA standalone web page built for a single campaign goal, designed to maximise conversions by removing distractions and focusing visitors on one action.View full definition → with an advertising pixel firing on the "check your eligibility" step, transmitting the fact that this device belongs to someone seeking treatment for a named condition. Nobody in the marketing team decided to sell health data. The tag manager did it.

Two more edges worth holding:

• The FTC's Health Products Compliance Guidance (December 2022) governs claim substantiation for OTC products, supplements and health devices that fall outside prescription drug promotion authority. "Competent and reliable scientific evidence" is the standard, and it applies to the unbranded wellness content marketingcontent marketingA strategy of creating and distributing valuable content to attract, engage and retain a defined target audience, rather than pitching products directly.View full definition → teams often treat as low risk.
• After the Supreme Court's 2021 decision in *AMG Capital Management v. FTC* cut back the FTC's ability to obtain monetary relief under Section 13(b), the agency leans on rules that carry their own civil penalty authority. That is why the Health Breach Notification Rule, rather than a general unfairness theory, produced a cheque from GoodRx.

After it ships: Form FDA 2253 and the cost of a correction

In the US, promotional materials for prescription products are filed on Form FDA 2253 at the time of initial dissemination. That is a surveillance record, not a pre-approval. Nobody at FDA blesses your Instagram caption before it publishes, which is why the internal sign-off gate the pre-launch check lesson walks through carries the real load.

What arrives afterwards, if something is wrong, is a letter. OPDP publishes only a handful of letters in a typical recent year, which tempts teams to price the risk as near zero. That misreads the cost. A letter usually demands a corrective action plan, asset removal, and sometimes corrective communication to the same audience. Enforcement letters are public and permanent in FDA's Warning Letters database, the trade and consumer press re-report the original omission with the regulator's language attached, and the influencer's own audience sees the takedown. The Duchesnay episode is still the most cited social-media promotion case a decade later, which is a longer tail than any single campaign was ever going to buy.

A word on persuasion vs. compliance

Fair balance does not neuter creative work. It changes what you are allowed to leave implicit.

You can still lead with a benefit statement, use patient voices, and design an asset that holds attention. What you cannot do is let the benefit stand alone while risk disclosure is an afterthought or a link. The replacement Diclegis post after the FDA letter proves the point: it carried the indication, the drowsiness warning and a route to full safety information, and it was still a personal endorsement from the same person to the same audience. The integration is the craft.

Key Takeaways

• Fair balance is about prominence, not presence: risk information must travel in the same message as the claim, with comparable size, placement and duration. In character-limited or muted-autoplay formats, that often means the platform is wrong for the claim.
• The Duchesnay Diclegis Instagram post drew an OPDP untitled letter for carrying efficacy claims with no risk information and for omitting material facts about the studied population.
• Paid influencer content answers to two regimes at once: OPDP on fair balance and the FTC on clear disclosure of the material connection. Edited captions, expiring stories and brand replies to off-label comments are the usual leak points.
• The FTC's GoodRx action ($1.5 million civil penalty, February 2023) ran on the Health Breach Notification Rule rather than HIPAA, which is exactly how non-covered patient-facing properties get caught. Audit your tags, not just your copy.
• Form FDA 2253 is filed at first use, not for pre-approval, so enforcement lands after publication and the cost is corrective action plus a permanent public record.